TP53 and carcinoma: Preliminary NGS analyses performed on the single aneuploid CTCs and CECs detected by SE-iFISH in a population of lung, breast, and renal cell carcinoma patients indicated that, in contrast to the relatively low mutation frequency of TP53 in primary carcinoma lesions, a high mutation frequency of tumor suppressor gene TP53, encoding the tumor suppressor protein p53 [69], was shown in every aneuploid CTC across all the cancer patients subjected to SE-iFISH.